Summary of the Conference Call for 石四药集团 (Sihuan Pharmaceutical Group) Company Overview - **Company**: Sihuan Pharmaceutical Group - **Date of Call**: March 27, 2026 Key Financial Performance - **2025 Net Profit**: HKD 471 million, a decrease of 55.6% year-on-year, but the decline is less severe compared to the mid-year results [2][3] - **Sales Revenue**: Approximately HKD 4.165 billion, down 27.8% year-on-year; in RMB, it is about CNY 3.812 billion [3] - **Gross Margin**: Approximately 41.6%, down 8.8 percentage points year-on-year due to increased revenue share from centralized procurement and price declines in existing products [3] - **Dividend**: Maintained at HKD 0.08 per share, with a payout ratio close to 50% [3] - **Cash and Cash Equivalents**: Approximately HKD 1.69 billion at the end of 2025, an increase of HKD 433 million from the previous year [3] Business Segments and Growth Strategies Intravenous Solutions - **2026 Sales Target**: 1.85 billion bags (+20% growth) driven by the replacement of plastic bottles with upright bags and increased procurement [2][6] - **2025 Performance**: Sales volume of 1.536 billion bags, down 24.5%; sales revenue of HKD 2.485 billion, down 33.5% [6] Export Business - **2025 Export Growth**: Formulations export revenue increased by 35%, targeting HKD 300-350 million in 2026 [2][5] - **Packaging Materials**: Expected to double in growth, with significant market entry into Southeast Asia, South America, and the Middle East [5] Centralized Procurement - **Market Share**: Significant advantages in centralized procurement, with 12 products won in the 11th batch and plans to participate in 46 products in the 12th batch [2][4] Active Pharmaceutical Ingredients (APIs) - **Cost Advantage**: Self-produced calcium chloride and magnesium chloride at costs significantly lower than market prices (1/7 to 1/50) [2][11] - **2026 Outlook**: Expected recovery in business performance [2][11] Innovative Drugs - **Clinical Trials**: Plans to submit for Phase I clinical trials for pulmonary hypertension and epilepsy drugs by the end of 2026 [2][12] - **Partnerships**: Exclusive authorization for a sugar-free peritoneal dialysis solution from a Swiss company [2][17] Market Dynamics and Competitive Landscape - **Price Trends**: Continuous price decline in intravenous products, with a recent stabilization and expected price increases due to rising raw material costs [21][22] - **Market Share Concentration**: Centralized procurement is leading to increased market share for top-tier suppliers [22][23] Future Outlook - **2026 Goals**: Targeting 20% growth in intravenous solutions, with a focus on specialized products rather than standard saline solutions [15][22] - **Innovation Focus**: Plans to submit 2-3 Phase I clinical projects annually, leveraging AI for drug discovery [15][17] - **Export Revenue Target**: Expected formulation export revenue of HKD 300-350 million in 2026, with potential for further growth [17][18] Conclusion - **Management Confidence**: Despite recent challenges, the company is optimistic about returning to 2020 performance levels within two years, emphasizing shareholder value and strategic growth initiatives [24]

Group 1 - The core viewpoint of the news is that Jimin Health has experienced fluctuations in its stock performance and financial metrics, indicating potential investment opportunities and risks [1][2]. - On February 25, Jimin Health's stock rose by 1.68%, with a trading volume of 75.77 million yuan. The net financing purchase was 211,300 yuan, with a total financing and margin balance of 169 million yuan [1]. - The financing balance of Jimin Health is 169 million yuan, accounting for 3.55% of its market capitalization, which is below the 20th percentile level over the past year, indicating a low financing level [1]. - In terms of short selling, Jimin Health had no shares repaid on February 25, with 300 shares sold short, amounting to 2,721 yuan. The short selling balance is 8,070 yuan, which is above the 80th percentile level over the past year, indicating a high level of short selling [1]. Group 2 - As of September 30, the number of shareholders of Jimin Health increased by 107% to 58,100, while the average circulating shares per person decreased by 51.69% to 9,035 shares [2]. - For the period from January to September 2025, Jimin Health reported a revenue of 545 million yuan, a year-on-year decrease of 20.21%. The net profit attributable to the parent company was -77.15 million yuan, a significant year-on-year decrease of 371.51% [2]. - Since its A-share listing, Jimin Health has distributed a total of 127 million yuan in dividends, with 10.74 million yuan distributed in the last three years [3].

Group 1 - The core viewpoint of the news is that Jimin Health has experienced a decline in stock price and significant changes in financing activities, indicating potential liquidity issues and investor sentiment challenges [1][2] Group 2 - On January 15, Jimin Health's stock fell by 1.95%, with a trading volume of 145 million yuan. The financing buy-in amount was 6.0087 million yuan, while the financing repayment was 11.2016 million yuan, resulting in a net financing outflow of 5.1929 million yuan [1] - As of January 15, the total balance of margin trading for Jimin Health was 222 million yuan, which represents 4.42% of its market capitalization. This financing balance is above the 60th percentile of the past year, indicating a high level [1] - In terms of securities lending, Jimin Health repaid 100 shares on January 15, with no shares sold, resulting in a securities lending balance of 5.26 million yuan, which is above the 50th percentile of the past year [1] Group 3 - As of September 30, the number of shareholders for Jimin Health increased to 58,100, a rise of 107%. However, the average number of circulating shares per person decreased by 51.69% to 9,035 shares [2] - For the period from January to September 2025, Jimin Health reported a revenue of 545 million yuan, a year-on-year decrease of 20.21%. The net profit attributable to shareholders was -77.1504 million yuan, a significant decline of 371.51% [2] Group 4 - Since its A-share listing, Jimin Health has distributed a total of 127 million yuan in dividends, with 10.7447 million yuan distributed over the past three years [3]

Core Insights - The social security fund, known as the "national team," has faced significant losses on recent investments in various companies, including Zhongchong Co. and Poly Developments, despite their strong market positions and low price-to-book ratios [1][3][5] - A trend has emerged where the social security fund's investments in leading companies across multiple sectors have resulted in substantial unrealized losses, with many stocks down over 50% over three years [3][5] - The fund's strategy appears to focus on acquiring shares in industry leaders at low valuations, reminiscent of its approach during market downturns in 2018 [5][6] Investment Performance - The social security fund's recent investments include 1.44 million shares of Zhongchong Co., which has a 9% market share in the domestic pet food market, but the stock price has declined since the purchase [1] - Poly Developments, the 2024 real estate sales champion, has a price-to-book ratio of 0.47, yet its stock continues to hit new lows [3] - The fund's investment in China Metallurgical Group resulted in a short-term loss exceeding 80 million yuan after acquiring 100 million shares [3] Sector Analysis - In the aluminum sector, the fund increased its holdings in Nanshan Aluminum to 164 million shares, making it the fifth-largest shareholder, but the stock price has also fallen [3] - The renewable energy sector saw the fund invest in Jiazhe New Energy with 19.45 million shares, despite the company's high gross margin of 57.6% [3] - In the pharmaceutical industry, the fund acquired 13.94 million shares of Kelun Pharmaceutical, which has a market share of over 40% in large-volume parenterals, but the stock price has not improved [5] Long-term Strategy - The social security fund's investment approach reflects a preference for industry leaders, with recent acquisitions spanning real estate, agriculture, mining, and high-end manufacturing [5][6] - The fund's investments are based on thorough research, targeting companies with strong fundamentals that have not yet been fully reflected in their stock prices [11] - The fund's long-term investment horizon is evident, as it continues to invest in companies despite short-term market fluctuations [6][8] Market Trends - The fund's investments align with broader industry trends, such as the focus on food security and the demand for intelligent automotive technologies [6] - The global demand in certain sectors has decreased by 10%, while companies are increasing R&D investments, which may impact short-term profitability but enhance long-term efficiency [8] - Policy changes are affecting valuation systems, with state-owned enterprises being urged to focus on core responsibilities, leading to asset divestitures that may impact market perceptions [9]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical has experienced a continuous increase in stock price, rising for seven consecutive days with a cumulative increase of 17.86% [1] - As of the report, Kelun Pharmaceutical's stock price is 33.98 yuan per share, with a total market capitalization of 54.302 billion yuan and a trading volume of 876 million yuan [1] - The company's main business involves the development, production, and sales of large-volume infusion products, with revenue composition being 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Shenwan Hongyuan has a significant position in Kelun Pharmaceutical, with a holding of 106,000 shares, representing 1.56% of the fund's net value [2] - The fund, Shenwan Hongyuan CSI Pharmaceutical Bio Index A, has seen a floating profit of approximately 54,620 yuan during the seven-day stock price increase [2] - The fund has a total asset size of 2.22 billion yuan, with a year-to-date return of 6.59% and a one-year return of 20.61% [2]

Group 1 - The company Kelong Pharmaceutical announced a share buyback plan with a total amount between 50 million and 100 million yuan, at a maximum price of 35.00 yuan per share, funded by its own resources, within a 12-month period [1] - The current stock price of Kelong Pharmaceutical is 30.18 yuan, reflecting a year-to-date increase of 2.83%, with the proposed buyback price being 15.97% higher than the current price [1] - Kelong Pharmaceutical's main business includes the development, production, and sales of large-volume infusion products, with revenue composition being 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from R&D projects, and 3.33% from others [1] Group 2 - As of September 30, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period, while the average circulating shares per person decreased by 7.70% to 35,200 shares [2] - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] Group 3 - Kelong Pharmaceutical has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [3] - As of December 31, 2025, the top ten circulating shareholders include notable entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their shareholdings [3]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.01% on January 5, 2025, and a total market capitalization of 478.46 billion yuan [1] - As of January 5, 2025, the stock price is reported at 29.94 yuan per share, with a trading volume of 1.64 billion yuan and a turnover rate of 0.43% [1] - The company has experienced a year-to-date stock price increase of 2.01%, but has seen declines of 1.77% over the last five trading days, 12.20% over the last 20 days, and 16.68% over the last 60 days [1] Group 2 - For the period from January to September 2025, Kelun Pharmaceutical reported a revenue of 13.277 billion yuan, representing a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [2] Group 3 - As of September 30, 2025, the number of shareholders for Kelun Pharmaceutical increased to 37,100, marking an 8.35% rise from the previous period, while the average number of circulating shares per person decreased by 7.70% to 35,200 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings for several institutional investors, such as China Europe Medical Health Mixed Fund and Industrial Bank Frontier Medical Stock A [3]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.05% on December 31, reaching 29.42 yuan per share, and a total market capitalization of 47.015 billion yuan [1] - As of September 30, 2025, Kelun Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company has a diverse revenue structure, with 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1] Group 2 - Kelun Pharmaceutical has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed in the last three years [3] - The number of shareholders increased to 37,100 as of September 30, 2025, reflecting an 8.35% rise, while the average number of circulating shares per person decreased by 7.70% to 35,200 shares [2] - Major shareholders include China Europe Medical Health Mixed A, holding 40.0624 million shares, and Hong Kong Central Clearing Limited, holding 34.728 million shares, both of which have seen a reduction in their holdings compared to the previous period [3]

Core Viewpoint - Kelong Pharmaceutical's stock has experienced a decline, with a current price of 29.87 yuan per share and a market capitalization of 47.734 billion yuan, reflecting a challenging financial performance in recent months [1] Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company's stock price has increased by 1.93% year-to-date, but has seen declines of 5.74% over the last five trading days, 13.22% over the last 20 days, and 20.27% over the last 60 days [1] Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period, with an average of 35,200 circulating shares per shareholder, a decrease of 7.70% [2] - The company has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed in the last three years [3] Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, notable changes include a decrease in holdings by major funds such as China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]

Core Viewpoint - Kolun Pharmaceutical experienced a 2.16% increase in stock price on December 19, with a trading volume of 313 million yuan, indicating a notable market interest in the company [1]. Financing Summary - On December 19, Kolun Pharmaceutical had a financing buy amount of 11.95 million yuan and a financing repayment of 19.66 million yuan, resulting in a net financing buy of -7.71 million yuan [1]. - As of December 19, the total financing and securities lending balance for Kolun Pharmaceutical was 944 million yuan, with the financing balance at 937 million yuan, accounting for 1.85% of the circulating market value, which is above the 70th percentile of the past year [1]. - The securities lending aspect showed a repayment of 900 shares with no shares sold, and a securities lending balance of 6.48 million yuan, exceeding the 80th percentile of the past year [1]. Business Performance Summary - As of September 30, Kolun Pharmaceutical reported a total of 37,100 shareholders, an increase of 8.35% from the previous period, while the average circulating shares per person decreased by 7.70% to 35,200 shares [2]. - For the period from January to September 2025, Kolun Pharmaceutical achieved an operating revenue of 13.28 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.20 billion yuan, down 51.41% year-on-year [2]. - Since its A-share listing, Kolun Pharmaceutical has distributed a total of 6.90 billion yuan in dividends, with 3.59 billion yuan distributed over the past three years [2]. Institutional Holdings Summary - As of September 30, 2025, the top ten circulating shareholders of Kolun Pharmaceutical included notable institutions such as China Europe Medical Health Mixed Fund, which held 40.06 million shares, a decrease of 2.54 million shares from the previous period [3]. - Other significant shareholders included Hong Kong Central Clearing Limited with 34.73 million shares (down 5.26 million shares), and Industrial Bank's Frontier Medical Stock A with 20 million shares (down 700,880 shares) [3]. - The top ten shareholders saw a general trend of reduced holdings, with the exception of Guangfa Multi-Factor Mixed Fund, which maintained its holding at 24.23 million shares [3].